Clinical profile of primary biliary cirrhosis with features of autoimmune hepatitis: Importance of corticosteroid therapy
- 19 August 2013
- journal article
- Published by Wiley in Hepatology Research
- Vol. 44 (9), 947-955
- https://doi.org/10.1111/hepr.12210
Abstract
The aim of this study was to elucidate the clinical and histological features, response to corticosteroid therapy and long-term outcome of primary biliary cirrhosis (PBC) with features of autoimmune hepatitis (AIH). Among 280 PBC patients under ursodeoxycholic acid administration, we identified 28 patients with AIH features fulfilling the following criteria: sustained high levels of serum aminotransferases and high immunoglobulin G levels with positivity for antinuclear antibodies or anti-smooth muscle antibodies (ASMA) and/or histological features of moderate to severe interface hepatitis or moderate to severe lobular hepatitis. We analyzed PBC patients with AIH features, focusing mainly on therapeutic responses to corticosteroids. Patients with PBC with AIH features included 26 women (93%). Their median age was 55 years, and the median follow-up period was 7.5 years. Eight of these 28 patients were not actually treated with corticosteroids due to medical conditions. Among the 20 patients receiving corticosteroid therapy, 15 were responders and five were non-responders. A high alkaline phosphatase (ALP) level, negativity for ASMA and positivity for gp210 were identified as risk factors for lack of a response to corticosteroid therapy. Among 28 PBC patients with AIH features, the responders to corticosteroids had an excellent prognosis, while those who could not be treated with corticosteroids and non-responders to corticosteroids had a poor outcome. Patients with PBC with AIH features benefit from corticosteroid therapy. Features of PBC such as high ALP level, negativity for ASMA and positivity for gp210 appear to predict a poor response to corticosteroids.Keywords
This publication has 26 references indexed in Scilit:
- Prevalence of Primary Biliary Cirrhosis–Autoimmune Hepatitis Overlap SyndromeClinical Gastroenterology and Hepatology, 2011
- Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long‐term outcome and survivalAlimentary Pharmacology & Therapeutics, 2008
- Predictive role of anti‐gp210 and anticentromere antibodies in long‐term outcome of primary biliary cirrhosisHepatology Research, 2007
- Long term outcome and response to therapy of primary biliary cirrhosis—autoimmune hepatitis overlap syndromeJournal of Hepatology, 2006
- Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosisJournal of Hepatology, 2005
- A scoring system for primary biliary cirrhosis and its application for variant forms of autoimmune liver diseaseThe Esophagus, 2003
- International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitisJournal of Hepatology, 1999
- Clinicopathological study of autoimmune hepatitis patients with or without hypergammaglobulinemia.Kanzo, 1999
- Ein der chronisch-destruierenden nicht-eitrigen Cholangitis ähnliches Krankheitsbild mit antinukleären Antikörpern (Immuncholangitis)*Deutsche Medizinische Wochenschrift (1946), 1987
- Manifestations of nonsuppurative cholangitis in chronic hepatobiliary diseases: morphologic spectrum, clinical correlations and terminologyLiver International, 1984